Effects of angiotensin II type I receptor blocker losartan on orthodontic tooth movement

Moura, Adriana Pedrosa; Montalvany-Antonucci, Carina Cristina; Taddei, Silvana Rodrigues de Albuquerque; Queiroz-Junior, Celso Martins; Biguetti, Cláudia Cristina; Garlet, Gustavo P.; Ferreira, Anderson J.; Teixeira, Mauro Martins; Silva, Tarcı́lia Aparecida; Andrade, Ildeu

doi:10.1016/j.ajodo.2015.09.019

Cited by 17 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, upregulation of AT2 receptor has been observed with the use of losartan, 29 suggesting that blockade of AT1R by using antagonist produces endogenous‐free Ang II that may stimulate AT2 47 . In mice, losartan decreased osteoclasts markers, such as RANK and RANKL, whereas OPG was increased 48 . Olmesartan, another AT1R antagonist, reduced inflammation and bone loss in rats, due to decreasing levels of cyclooxygenase‐2, metalloproteinase (MMP)‐2, MMP‐9, RANKL, and RANK and increasing OPG 28 .…”

Section: Discussionmentioning

confidence: 99%

“…47 In mice, losartan decreased osteoclasts markers, such as RANK and RANKL, whereas OPG was increased. 48 Olmesartan, another AT1R antagonist, reduced inflammation and bone loss in rats, due to decreasing levels of cyclooxygenase-2, metalloproteinase (MMP)-2, MMP-9, RANKL, and RANK and increasing OPG. 28 Taking this into account, although related to in vivo situations, it can be suggested that increased OPG observed in this study with AT1R knockdown in HGF may have occurred by stimulation of AT2 Figure 5.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Angiotensin II Type 1 Receptor Knockdown Impairs Interleukin‐1β‐Induced Cytokines in Human Periodontal Fibroblasts

Gabriele

Morandini

Dionísio

et al. 2017

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Angiotensin II Type 1 Receptor Knockdown Impairs Interleukin‐1β‐Induced Cytokines in Human Periodontal Fibroblasts

Gabriele

Morandini

Dionísio

et al. 2017

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…SHR rats develop hypertension around 5–6 weeks of age (Okamoto & Aoki, ). Losartan at least partially reduced periodontitis (Santos et al, ) and orthodontic tooth movement in SHR rats (Moura et al, ). When untreated, SHR present delayed alveolar bone healing suggesting that also osseointegration could be negatively affected (Manrique et al, ).…”

Section: Introductionmentioning

confidence: 99%

Losartan reverses impaired osseointegration in spontaneously hypertensive rats

Mulinari‐Santos

Batista

Kirchweger

et al. 2018

Clinical Oral Implants Res

View full text Add to dashboard Cite

Objective: Hypertension is not only associated with cardiovascular diseases but also with alterations in bone quality. Hypertension therefore might be a risk factor for osseointegration. Preclinical studies suggest that losartan, an angiotensin II receptor blocker widely used to treat hypertension, has a beneficial effect in graft consolidation. Here, we determine the effect of hypertension and losartan on osseointegration. Methods:We used spontaneously hypertensive rats (SHR) and normotensive Wistar albinus rats receiving losartan (30 mg/kg, p.o.) or left untreated. After 1 week, titanium miniscrews were inserted into the tibia. Sixty days after implantation, implant stability was evaluated by removal torque measurement considered the primary endpoint. Microcomputed tomography and histomorphometric analysis were secondary endpoints.Results: Losartan increased the removal torque in the hypertensive SHR group to levels of the Wistar controls. While the cortical parameters of osseointegration remained unchanged, losartan increased medullary bone formation. Microcomputed tomography revealed a higher bone volume per tissue volume and trabecular thickness in the SHR rats treated with losartan. Histomorphometric analysis further showed that losartan significantly increased the thickness of newly formed bone in medullary area in hypertensive SHR rats. Losartan did not significantly alter the parameters of osseointegration in normotensive rats. Conclusions:The data presented suggest that the angiotensin II receptor antagonist losartan increases the medullary parameters of osseointegration in a tibia model of spontaneously hypertensive rats. Considering the study limitations, understanding the impact of hypertension and the respective drugs on osseointegration requires further research. K E Y W O R D Sbone, losartan, osseointegration, renin-angiotensin system, spontaneously hypertensive rats | 1127 MULINARI-SANTOS eT AL.

show abstract

“…In the following list, 15 studies were excluded based on the full-text analysis. Overall, 17 studies (Araujo et al, 2013a;Araujo et al, 2013b;Araújo et al, 2014; Dionisio et al, 2019; Goncalves-Zillo et al, 2013; Li et al, 2019;Matos et al, 2013;Matos et al, 2014;Matos et al, 2015;Matos et al, 2016;Matos et al, 2019;Moura et al, 2016;Mulinari-Santos et al, 2019;Oliveira et al, 2019;Queiroz-Junior et al, 2015;Santos et al, 2015;Suda et al, 2013) were included in the qualitative synthesis ( Fig. 2).…”

Section: Data Management and Assessment Of Treatment Effectsmentioning

confidence: 99%

The tissue renin-angiotensin system (tRAS) and the impact of its inhibition on inflammation and bone loss in the periodontal tissue

Saravi

Lang²,

Ülkümen³

et al. 2020

eCM

View full text Add to dashboard Cite

Recently, the existence of the tissue renin-angiotensin system (tRAS) has been described for multiple tissues in humans, suggesting its fundamental role in the progression of inflammation and fibrosis. Evidence arises that tRAS might have an impact on the progression of periodontitis and bone loss. However, neither the role of tRAS nor its impact as a therapeutic target have been systematically evaluated for periodontal tissue. The present study sought to characterise tRAS in the periodontal tissue and the effect of its inhibition on periodontal inflammation and bone loss. This systematic review was performed according to the preferred reporting items for systematic reviews and meta analyses (PRISMA) statement. Literature was searched using Web of Science core collection (Web of Science), Medline (Ovid), Cochrane central register of controlled trials (Ovid), Cochrane database of systematic reviews (Ovid), Google Scholar databases and the references of the retrieved studies in March 2020. Information on study design, sample size, population, procedure, type of intervention, observation time, as well as information on sources of bias, was extracted and evaluated. From 455 identified articles, 17 were included in the qualitative synthesis and 11 were included in the quantitative synthesis. Outcomes of studies indicated that the inhibition of tRAS components led to a reduction of periodontal bone loss and inflammation, dependent on the inhibitor used. The findings suggested an important role of tRAS in the periodontal tissue and indicate a potential therapeutic approach for periodontal diseases.

show abstract

Effects of angiotensin II type I receptor blocker losartan on orthodontic tooth movement

Cited by 17 publications

References 25 publications

Angiotensin II Type 1 Receptor Knockdown Impairs Interleukin‐1β‐Induced Cytokines in Human Periodontal Fibroblasts

Angiotensin II Type 1 Receptor Knockdown Impairs Interleukin‐1β‐Induced Cytokines in Human Periodontal Fibroblasts

Losartan reverses impaired osseointegration in spontaneously hypertensive rats

The tissue renin-angiotensin system (tRAS) and the impact of its inhibition on inflammation and bone loss in the periodontal tissue

Contact Info

Product

Resources

About